TREATMENT OF SEVERE DEPRESSION WITH DESIPRAMINE, A METABOLITE OF IMIPRAMINE
Abstract
Desipramine, an active metabolite of imipramine, was administered to 129 patients with severe depressive disorders. The majority had a history of 1 to 4 depressive attacks. In most cases, the drug was given for 2 to 4 months in daily doses of 75 or 100 mg. (i.m.) for a few days, followed by 100 to 150 mg. orally, thereafter. Tranquilizers were given concurrently as required to control agitation, anxiety or insomnia.
Desipramine produced a satisfactory clinical response in 99 (76.4%) patients. Compared to imipramine, used in previous studies, the new drug seems to be slightly more potent on a dose-size basis; it has a faster onset of action, evident in 2 to 7 days, and side effects appear to be milder and of shorter duration.
Because of its rapid onset of action and mild side effects, desipramine may prove particularly useful in reducing the need for prolonged hospitalization in severe depressive conditions.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).